New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
|Slideshows|May 31, 2018
New FDA Warning
Author(s)James Phelps, MD
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
Brenipatide for Alcohol Use Disorder: Emerging Findings
3
New Adult ADHD Guidelines: What Resources Are Coming Soon
4
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
5